NTLA

#1848
Intellia Therapeutics, Inc
13.7800
-0.29%
セクター:
ベース:
利益通貨:
日中レンジ
13.7800
13.7800
1年のレンジ
7.9500
17.0900
1日の変化
-0.29%
月次変化
-7.89%
6か月変化
+0.44%
1年の変化
+0.44%
以前の終値
13.8200
Open
13.7800
Bid
Ask
Low
13.7800
High
13.7800
ボリューム
144
Open full chart

Financials

Overview 明細書 Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.5184 B
  • Employee 598
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.36
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

ニュース